Table 5.

Adverse events

	Subjects, N = 24
Overall adverse events	17 (70.8)
Any	17 (70.8)
Seriousa	0 (0.0)
Fatal	0 (0.0)
Common adverse events (reported in ≥ 10% of subjects after erenumab treatment)
Headache	8 (33.3)
Upper respiratory tract infection	4 (16.7)
Fatigue	3 (12.5)

^aA serious adverse event was defined as an event that was fatal or life threatening, required inpatient hospitalization or prolongation of existing hospitalization, caused persistent or substantial disability or incapacity, caused congenital anomaly or birth defect, or was considered by the investigator to be medically important